# QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

> **NCT00807612** · PHASE1,PHASE2 · TERMINATED · sponsor: **NantCell, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Advanced Squamous Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** AMG 479
- **BIOLOGICAL:** AMG 479
- **DRUG:** Carboplatin
- **BIOLOGICAL:** AMG 479
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00807612
- **Lead sponsor:** NantCell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Study was closed due to administrative decision
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00807612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00807612, "QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00807612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*